Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 10/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 3/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.41 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nefextinib SCHEMBL30274682 | 1.00 | ALK (0.54) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| Nefextinib SCHEMBL18410078 | 1.00 | ALK (0.54) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| Nefextinib SCHEMBL27146129 | 0.94 | ALK (0.49) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL21318243 | 0.92 | ALK (0.54) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL18410197 | 0.91 | ALK (0.60) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL18410203 | 0.90 | ALK (0.64) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL28997096 | 0.90 | FGFR1 (0.45) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL20429743 | 0.89 | ALK (0.51) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL18410173 | 0.89 | ALK (0.51) | ALKFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL18410122 | 0.87 | MYLK4 (0.46) | ALKJAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027230-A1 | DRUG DELIVERY SYSTEM, TREATMENT KIT, AND METHOD FOR INHIBITING PROLIFERATION OR METASTASIS OF CANCER CELL | CHINA MEDICAL UNIVERSITY (TW) | 2026-01-29 | — | — | US | claimed |
| EP-4683635-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | Boundless Bio, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2025-06-12 | — | — | US | claimed |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | AROG PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4484429-A1 | COMPOUND AND USE THEREOF | OnQuality Pharmaceuticals China Ltd. (CN) | 2025-01-01 | — | — | EP | claimed |
| CN-119072303-A | Combined preparation of sitagliptin | 大塚制药株式会社 | 2024-12-03 | — | — | CN | claimed |
| CN-118715226-A | Compounds and uses thereof | 上海岸阔医药科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| WO-2024196923-A1 | USES OF A CHECKPOINT KINASE 1 (CHK1) INHIBITOR | BOUNDLESS BIO, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240108633-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | ONQUALITY PHARMACEUTICALS CHINA LTD. (CN) | 2024-04-04 | — | — | US | claimed |
| US-20240100040-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | claimed |
| US-11857546-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | AROG PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| CN-116710141-A | Methods for preventing or treating antitumor agent-related diseases or conditions | 上海岸阔医药科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| WO-2023155905-A1 | COMPOUND AND USE THEREOF | 上海岸阔医药科技有限公司 | 2023-08-24 | — | — | WO | claimed |
| US-20230128591-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | claimed |
| WO-2022143628-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | 上海岸阔医药科技有限公司 | 2022-07-07 | — | — | WO | claimed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| WO-2022053029-A1 | SCREENING METHOD FOR FGFR INHIBITOR | 广州再极医药科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| CN-114164248-A | FGFR inhibitor screening method | 广州再极医药科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027230-A1 | DRUG DELIVERY SYSTEM, TREATMENT KIT, AND METHOD FOR INHIBITING PROLIFERATION OR METASTASIS OF CANCER CELL | LDLR, NPC1L1, LPXN | ALK 524/4885FGFR1 2480/4885FGFR2 3162/4885 |
| US-11857546-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | FLT3, RET, MKI67 | ALK 26/4885FGFR1 4/4885FGFR2 28/4885 |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | FLT3, RET, MKI67 | ALK 26/4885FGFR1 4/4885FGFR2 28/4885 |
| US-20230128591-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | ALK 26/4885FGFR1 4/4885FGFR2 28/4885 |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | DCTD, EZH2, DUT | ALK 2799/4885FGFR1 3216/4885FGFR2 1976/4885 |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | ALK 26/4885FGFR1 4/4885FGFR2 28/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | ALK 93/4885FGFR1 149/4885FGFR2 434/4885 |
| US-20240100040-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | ALK 26/4885FGFR1 4/4885FGFR2 28/4885 |
| US-20250188088-A1 | COMPOUND AND USE THEREOF | CYP17A1, CYP11B2, CYP21A2 | ALK 3919/4885FGFR1 4402/4885FGFR2 4490/4885 |
| US-20240108633-A1 | METHOD FOR PREVENTING OR TREATING DISEASE OR CONDITION ASSOCIATED WITH ANTITUMOR AGENT | JAK2, JAK1, JAK3 | ALK 177/4885FGFR1 1040/4885FGFR2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.